AIM: To investigate the efficacy and safety of paclitaxel albumin assisted platinum chemotherapy in the treatment of recurrent and metastatic cervical cancer based on tumor factors and inflammatory status. METHODS: A total of 100 patients with recurrent and metastatic cervical cancer in our hospital from January 2020 to January 2023 were randomly divided into two groups: 50 patients in the control group were treated with paclitaxel-assisted nedaplatin regimen, and 50 patients in the study group were treated with paclitaxel-assisted nedaplatin regimen. The short-term efficacy, tumor factors, inflammatory factors, relapse-metastasis related indexes, quality of life, functional status and adverse reactions were compared between the two groups. RESULTS: The total remission rate of the study group (72.00%) was higher than that of the control group (48.00%) (P<0.05). In the study group, after one and three cycles of treatment, serum cytokeratin 19 fragment antigen 21-1 (CYFRA21-1), carbohydrate antigen 724 (CA724), squamous cell carcinoma antigen (SCC Ag), interleukin-4 (IL-4), interleukin-6 (IL-6), tumor necrosis factor-α(TNF-α) The levels of serum microrna-367 (mir-367), microrna-383 (mir-383), quality of life (QOL) and Karnofsky functional status score (KPS) in the tumor patients were significantly higher than those in the control group (P<0.05); There was no significant difference in the incidence of nausea/vomiting, diarrhea, fatigue, leukopenia and allergic reactions between the study group and the control group during treatment (P>0.05), but the total incidence of adverse reactions (12.00%) was lower than that of the control group (32.00%) (P<0.05). CONCLUSION: Paclitaxel albumin-assisted nedaplatin has a reliable effect in the treatment of recurrent and metastatic cervical cancer, which can further reduce the level of tumor factors, relieve inflammation, and has high safety.